A Vice President (VP) of Marketing at Cabaletta Bio develops and executes the commercial marketing strategy to transition the company from a clinical-stage biotechnology firm to a commercial leader in autoimmune cell therapies. Reporting directly to the Chief Commercial Officer (CCO). Create pre-launch and launch strategies for Cabaletta's lead CAR-T (Chimeric Antigen Receptor T cells for Autoimmunity) candidate, rese-cel (resecabtagene autoleucel), as it heads toward a targeted 2027 FDA filing for myositis, alongside a broader clinical portfolio spanning lupus, systemic sclerosis, and myasthenia gravis. Responsibilities: Launch & Commercialization Strategy: Architect and execute US commercial launch plans for rese-cel across multiple targeted autoimmune indications, preparing the market for the paradigm shift of CAR-T outside of oncology. Brand & Value Proposition: Define clinical branding, scientific narrative, and messaging frameworks that educate stakeholders on the "immune system reset" concept of autologous cell therapy without long-term immunosuppression. Function Building: Recruits, structures, and leads a high-performing commercial marketing team across healthcare professional (HCP) marketing, patient advocacy, digital strategy, and consumer awareness. Cross-Functional Collaboration: Partner closely with New Product Planning, Market Access, Medical Affairs, and Regulatory Affairs to ensure real-world customer insights shape clinical endpoints and site-of-care logistics. KOL & Advocate Engagement: Cultivate advisory relationships with key opinion leaders (KOLs), disease-specific medical societies, and patient advocacy groups in rheumatology, neurology, and dermatology. Agency & Budget Governance: Oversee selection, onboarding, and performance of therapeutic Agencies of Record (AoRs), managing a scaling commercial budget focused on multi-channel disease-state awareness. Qualifications: